Morgan Stanley raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $102 and keeps an Equal Weight rating on the shares. The key upside risk to the firm’s Equal Weight rating has played out with Sanofi’s (SNY) announced acquisition of Blueprint for $129 per share plus a non-tradeable CVR of up to $6 per share, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Neutral from Sell at Citi
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls